MAPK
Las MAPK son una familia de quinasas de proteínas involucradas en una variedad de procesos celulares, incluyendo crecimiento, proliferación, diferenciación y respuestas al estrés. La vía de señalización MAPK consta de varios niveles, incluidos ERK, JNK y p38 MAPK, cada uno con roles distintos en la función celular. La desregulación de la señalización MAPK está vinculada al cáncer, las enfermedades inflamatorias y los trastornos metabólicos. En CymitQuimica, ofrecemos una amplia gama de inhibidores y activadores de MAPK para apoyar su investigación en biología celular, transducción de señales y mecanismos de enfermedades.
Se han encontrado 892 productos para "MAPK". Se muestran los primeros 500.
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
Mitogen-activated protein kinase 1
CAS:Mitogen-activated protein kinase 1 (MAPK1) activates the p38/NF-κB pathway and regulates cellular processes in sepsis-associated diseases.Pureza:98%Forma y color:SolidHSND80
HSND80 (Compound 1) is an orally active MNK/p70S6K inhibitor, exhibiting a Kd value of 44 nM for MNK1 and 4 nM for MNK2. The residence time of HSND80 on MNK1 and MNK2 is 45 minutes and 58 minutes, respectively. HSND80 effectively inhibits non-small cell lung cancer (NSCLC) both in vitro and in vivo, and suppresses the growth of triple-negative breast cancer (TNBC) cells in vitro.Forma y color:Odour SolidS6 Kinase Substrate Peptide 32
S6 Kinase Substrate Peptide 32 is a peptide that measures the activity of kinases that phosphorylate ribosomal protein S6. It can also be used as a substrate.Fórmula:C149H270N56O49Pureza:98%Forma y color:SolidPeso molecular:3630.1MS432
MS432 is a highly selective PD0325901-based VHL-recruiting PROTAC degrader for MEK1 and MEK2.Fórmula:C50H65F3IN7O6SPureza:98%Forma y color:SolidPeso molecular:1076.06GGDPS-IN-1
GGDPS-IN-1 (Compound 37) is an inhibitor of geranylgeranyl diphosphate synthase (GGDPS) with an IC50 of 49.4 nM, disrupting protein geranylgeranylation in myeloma cells.Fórmula:C15H28N4O6P2Forma y color:SolidPeso molecular:422.14841GNE-9815
CAS:GNE-9815 (3-(2-cyanopropan-2-yl)-N-[2-fluoro-4-methyl-5-(7-methyl-8-oxo-7,8-dihydropyrido[2,3-d]pyridazin-3-yl)phenyl]benzamide) is a high kinase-selectiveFórmula:C26H22FN5O2Pureza:99.08% - 99.1%Forma y color:SolidPeso molecular:455.48Ref: TM-T9585
1mg60,00€5mg138,00€1mL*10mM (DMSO)138,00€10mg215,00€25mg358,00€50mg510,00€100mg692,00€500mg1.386,00€NecroX-2
CAS:NecroX-2 is a cell-permeable necrosis inhibitor with antioxidant properties. NecroX-2 selectively suppresses necrotic cell death triggered by oxidative stress. NecroX-2 does not confer protection against apoptosis induced by staurosporine or etoposide but shows protective effects under conditions such as cold shock, hypoxia, and oxidative stress in vitro.Fórmula:C25H32N4O4S2Pureza:97.12%Forma y color:SolidPeso molecular:516.68PROTAC MEK1 Degrader-1
CAS:PROTAC MEK1 Degrader-1, a targeted protein degradation agent, combines a MEK1 inhibitor with a von Hippel-Lindau ligand to effectively inhibit ERK1/2Fórmula:C53H66FIN8O11S2Pureza:98%Forma y color:SolidPeso molecular:1201.17R18
CAS:14.3.3 protein antagonist, blocks binding to Raf-1/Bad/ASK1/exoenzyme S, competitive, no phosphorylation needed, KD ~80 nM.Fórmula:C101H157N27O29S3Pureza:98%Forma y color:SolidPeso molecular:2309.69HPK1-IN-4
CAS:HPK1-IN-4 is an HPK1 (MAPK41) inhibitor with an IC 50 of 0.061 nM. HPK1-IN-4 is often used as a preclinical immunotherapy tool compound.Fórmula:C23H26N6O3Pureza:97.06%Forma y color:Yellow SolidPeso molecular:434.49Ref: TM-T40350
1mg123,00€5mg295,00€1mL*10mM (DMSO)326,00€10mg447,00€25mg782,00€50mg1.071,00€100mg1.468,00€(S,R,S)-AHPC-Me-C10-Br
CAS:(S,R,S)-AHPC-Me-C10-Br is a chemically synthesized conjugate and ligand-linker for E3 ligase, MS432 for MEK1/2 inhibitors and a VHL E3 ligase linker.Fórmula:C34H51BrN4O4SPureza:98.89%Forma y color:SolidPeso molecular:691.76ASP6918
ASP6918 is a potent, orally active KRAS G12C inhibitor with an IC50 of 0.028 µM. It inhibits cell growth and demonstrates antitumor activity.Fórmula:C36H43N7O3Forma y color:SolidPeso molecular:621.34274Antimicrobial agent-21
CAS:Antimicrobial agent-21 is a potent mitogen activated protein kinase inhibitor with antibacterial, anti-inflammatory and antitumor activity for the treatment ofFórmula:C18H13N3OSPureza:99.82%Forma y color:SolidPeso molecular:319.38Ref: TM-T67942
1mg54,00€5mg116,00€10mg172,00€1mL*10mM (DMSO)180,00€25mg278,00€50mg371,00€100mg510,00€200mg687,00€Fluconazole-PEG6-XMU-MP-9
Fluconazole-PEG6-XMU-MP-9, PEG-linked conjugate, fluconazole antifungal plus XMU-MP-9, promotes Nedd4-1 mediated K-Ras mutant degradation.Fórmula:C48H53F3N10O10SPureza:98.73%Peso molecular:1019.06ERK1/2 inhibitor 10
ERK1/2 inhibitor 10 (Compound 36c) is a potent inhibitor of ERK1 and ERK2, with IC50 values of 0.11 nM and 0.08 nM, respectively. It effectively hinders the phosphorylation of downstream substrates p90RSK and c-Myc. Additionally, ERK1/2 inhibitor 10 induces apoptosis and incomplete autophagy-related cell death. This compound demonstrates significant antitumor efficacy in models of triple-negative breast cancer and colorectal cancer harboring BRAF and RAS mutations.Fórmula:C23H20ClN5O2SPeso molecular:465.10262DS03090629
DS03090629, an orally active MEK inhibitor, functions by competitively inhibiting MEK activity in the presence of ATP. This compound demonstrates strong binding affinity to both MEK and phosphorylated MEK, with dissociation constants (Kd) of 0.11 and 0.15 nM, respectively. It has shown efficacy in suppressing the proliferation of melanoma cell lines that overexpress BRAF mutations, achieving IC50 values of 74.3 and 97.8 nM for BRAF V600E and MEK1 F53L transfected A375 cells, respectively. DS03090629 is thus considered promising for anti-melanoma therapies.Fórmula:C25H26ClN5O2Forma y color:SolidPeso molecular:463.96(RS)-G12Di-1
(RS)-G12Di-1 is a selective covalent inhibitor of K-Ras-G12D.Fórmula:C37H35FN6O4Forma y color:SolidPeso molecular:646.27038BI1701963
BI1701963 is an orally effective inhibitor that targets the SOS1 and KRAS interaction, specifically inhibiting the activation of KRAS by blocking its GTP loading. This compound is utilized in cancer research to explore potential therapeutic effects against KRAS-driven malignancies.Fórmula:C47H62N8O4SForma y color:SolidPeso molecular:835.11KRAS-IN-43
KRAS-IN-43 (Compound 9) is a broad-spectrum KRAS inhibitor with IC50 values of 0.15 μM for KRASG12V, 0.14 μM for KRASG12C, and 0.47 μM for wild-type KRAS. It disrupts the interaction between KRAS and cRAF and suppresses ERK phosphorylation. KRAS-IN-43 shows potential for research in KRAS mutation-associated cancers, including pancreatic, colorectal, and lung cancers.Forma y color:Odour SolidNK7-902 TFA
NK7-902 TFA is a CRBN molecular glue degrader of NEK7. It effectively degrades NEK7 in human primary monocytes and whole blood, yet only partially inhibits NLRP3-dependent IL-1β production. While NK7-902 TFA achieves deep and lasting NEK7 degradation, it temporarily blocks NLRP3 inflammasome activation in non-human primates when administered orally. Additionally, NK7-902 TFA demonstrates activity in mouse systems.Forma y color:Odour Solid
